Characteristics | Progression, n = 19 | Baseline No Progression, n = 37 | p | Progression, n = 19 | 1 Year No Progression, n = 37 | p |
---|---|---|---|---|---|---|
Clinical variables | ||||||
SJC66, median (range) | 3 (1–9) | 2 (0–4) | 0.25 | 0 (0–0) | 0 (0–0) | 0.39 |
TJC68, median (range) | 6 (2–16) | 3 (1–5.5) | 0.052 | 0 (0–0) | 0 (0–0) | 1.0 |
DAS28 | 4.5 ± 1.5 | 3.6 ± 1.1 | 0.050 | 1.8 ± 0.5 | 1.9 ± 0.5 | 0.65 |
SDAI | 22.2 ± 17.2 | 13.6 ± 8.0 | 0.050 | 3.1 ± 2.7 | 2.4 ± 2.2 | 0.42 |
HAQ score | 0.684 ± 0.671 | 0.451 ± 0.412 | 0.33 | 0.200 ± 0.287 | 0.164 ± 0.300 | 0.61 |
ESR, < 20 mm/h | 28.3 ± 20.9 | 19.8 ± 13.6 | 0.13 | 11.1 ± 8.0 | 15.5 ± 12.4 | 0.16 |
CRP, < 0.8 mg/dl | 2.1 ± 2.2 | 0.6 ± 0.8 | 0.01 | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.98 |
VAS pain, 0–100 mm | 43.9 ± 22.0 | 36.1 ± 19.7 | 0.28 | 22.1 ± 18.4 | 20.1 ± 22.5 | 0.46 |
PGA, 0–100 mm | 42.1 ± 22.3 | 35.4 ± 18.6 | 0.34 | 20.0 ± 19.6 | 16.3 ± 17.9 | 0.55 |
MRI variables | ||||||
RAMRIS synovitis (0–21) | 6.3 ± 3.4 | 5.9 ± 2.9 | 0.71 | 4.6 ± 2.0 | 3.7 ± 2.6 | 0.11 |
RAMRIS BME (0–69) | 8.3 ± 9.4 | 3.7 ± 6.1 | 0.09 | 4.8 ± 5.6 | 1.4 ± 2.6 | 0.03 |
RAMRIS erosion (0–230) | 9.9 ± 13.6 | 5.1 ± 5.1 | 0.55 | 13.5 ± 15.0 | 4.4 ± 5.0 | 0.001 |
Total RAMRIS (0–320) | 24.5 ± 20.0 | 14.9 ± 11.9 | 0.22 | 23.0 ± 20.2 | 10.1 ± 9.3 | 0.001 |
Tenosynovitis (0–26) | 7.0 ± 5.8 | 6.8 ± 6.7 | 0.55 | 3.4 ± 2.8 | 2.7 ± 4.9 | 0.059 |
CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints (tender and swollen); ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; MRI: magnetic resonance imaging; RAMRIS: Rheumatoid Arthritis MRI Score; SDAI: Simplified Disease Activity Index; SJC: swollen joint count in 66 joints; TJC: tender joint count in 68 joints; VAS: visual analog scale; PGA: patient global assessment; BME: bone marrow edema; RA: rheumatoid arthritis.